A Phase 1 interventional study of AG-181 in Phenylketonuria, sponsored by Agios Pharmaceuticals, Inc.. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.
Among the 93 studies in Phenylketonurias with a site in United States, this one is the 41st largest by planned enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 12 of the 20 other live ones, and was the 89th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:
Aptatek BioSciences, Inc · Sites in United States
Ages 1+
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65 · Healthy volunteers
Maze Therapeutics · Sites in United States, France, United Kingdom
Ages 18–75
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
University of Missouri-Columbia · Sites in United States
Ages 18–60 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 21 · Phase 3 16 · Phase 4 4
First in 1984; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 33 across the 63 interventional studies, 28 across the 29 observational. Of the 70 that completed or were terminated, 28 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 93 have an industry lead sponsor. The 10 most frequent:
Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Agios Pharmaceuticals, Inc. has 1 study filed under Phenylketonurias — fewer than ten, so there is no comparison to draw.
6 of the studies in Phenylketonurias with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06628128Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Long-Term Study of JNT-517 in Participants With Phenylketonuria | 2027-11-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT07713758Otsuka Pharmaceutical Development & Commercialization, Inc.A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney Function | 2027-02-09 |
| NCT07220265University of Missouri-ColumbiaImpact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers | 2027-03-01 |
| NCT07551921Aptatek BioSciences, IncPheCheck™ Validation Study | 2027-03-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 93 studies in Phenylketonurias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive AG-181 from Day 1 to Day 28.
Drug: AG-181
Subjects will receive AG-181.
Drug: AG-181
AG-181 film-coated tablets
Number of Subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to the Study Drug
Time frame: Up to Day 42
Plasma Concentration of AG-181
Time frame: Up to Day 28
Maximum Concentration (Cmax) of AG-181
Time frame: Up to Day 28
Time to Maximum (Peak) Concentration (Tmax) of AG-181
Time frame: Up to Day 28
Area Under the Concentration-Time Curve (AUC) of AG-181
Time frame: Up to Day 28
Apparent Total Body Clearance (CL/F) of AG-181
Time frame: Up to Day 28
Apparent Volume of Distribution in the Terminal Phase (Vz/F) of AG-181
Time frame: Up to Day 28
Change From Baseline in Phenylalanine (Phe) Concentration
Time frame: Baseline up to Day 28
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.